Annual average total casesa and average annual age-adjusted incidence ratesb with 95% confidence intervals for selected histopathologies (tumor types) for brain and other central nervous system tumors by grade, sex, age group at diagnosis, race, and hispanic ethnicity. (CBTRUS: Data provided by CDC’s NPCR and NCI’s SEER Program, 2015–2019)
| Histopathology (tumor type) . | Total . | Sex . | Age at diagnosis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male . | Female . | 0–14 years . | 15–39 years . | 40+ Years . | ||||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR 95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 21 362 | 5.94 (5.91–5.98) | 12 104 | 7.05 (6.99–7.10) | 9258 | 4.97 (4.92–5.02) | 1795 | 2.96 (2.90–3.02) | 3170 | 2.95 (2.91–3.00) | 16 397 | 9.90 (9.83–9.97) |
| Glioblastoma | 12 652 | 3.26 (3.24–3.29) | 7365 | 4.08 (4.04–4.12) | 5286 | 2.55 (2.52–2.59) | 93 | 0.15 (0.14–0.17) | 608 | 0.58 (0.56–0.60) | 11 951 | 7.03 (6.97–7.09) |
| Diffuse and anaplastic astrocytoma | 2936 | 0.87 (0.85–0.88) | 1623 | 0.98 (0.96–1.01) | 1313 | 0.75 (0.74–0.77) | 170 | 0.28 (0.26–0.30) | 932 | 0.86 (0.83–0.88) | 1834 | 1.16 (1.14–1.19) |
| WHO grade II(2)d | 896 | 0.28 (0.27–0.28) | 510 | 0.32 (0.31–0.33) | 386 | 0.23 (0.22–0.25) | 49 | 0.08 (0.07–0.09) | 388 | 0.36 (0.34–0.37) | 459 | 0.30 (0.29–0.32) |
| WHO grade III(3)d | 1382 | 0.40 (0.39–0.41) | 764 | 0.46 (0.44–0.47) | 618 | 0.35 (0.33–0.36) | 38 | 0.06 (0.05–0.07) | 406 | 0.37 (0.36–0.39) | 939 | 0.59 (0.57–0.61) |
Oligodendroglial tumorse | 1112 | 0.34 (0.33–0.35) | 615 | 0.39 (0.37–0.40) | 497 | 0.30 (0.29–0.31) | 15 | 0.02 (0.02–0.03) | 389 | 0.37 (0.35–0.38) | 708 | 0.48 (0.47–0.50) |
| WHO grade II(2)d | 608 | 0.19 (0.19–0.20) | 333 | 0.21 (0.20–0.22) | 276 | 0.17 (0.16–0.18) | 7 | 0.01 (0.01–0.02) | 244 | 0.23 (0.22–0.24) | 357 | 0.25 (0.24–0.27) |
| WHO grade III(3)d | 369 | 0.11 (0.11–0.12) | 204 | 0.13 (0.12–0.13) | 164 | 0.10 (0.09–0.10) | — | — | 104 | 0.10 (0.09–0.11) | 263 | 0.18 (0.17–0.19) |
| Pilocytic astrocytoma | 1068 | 0.36 (0.35–0.37) | 561 | 0.38 (0.36–0.39) | 507 | 0.35 (0.34–0.36) | 657 | 1.08 (1.04–1.12) | 293 | 0.27 (0.26–0.28) | 119 | 0.08 (0.07–0.09) |
| Molecularly-defined adult-type diffuse gliomaf | 12 674 | 3.34 (3.30–3.38) | 7400 | 4.11 (4.04–4.18) | 5273 | 2.66 (2.60–2.71) | 136 | 0.23 (0.20–0.26) | 1643 | 1.53 (1.47–1.58) | 10 894 | 6.39 (6.31–6.48) |
| Astrocytoma, IDH-mutant | 1421 | 0.44 (0.43–0.46) | 814 | 0.51 (0.49–0.54) | 608 | 0.38 (0.35–0.40) | 33 | 0.05 (0.04–0.07) | 740 | 0.68 (0.64–0.71) | 648 | 0.45 (0.42–0.47) |
| WHO grade II(2) d | 422 | 0.14 (0.13–0.15) | 248 | 0.16 (0.15–0.17) | 175 | 0.11 (0.10–0.13) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 149 | 0.11 (0.10–0.12) |
| WHO grade III(3) d | 474 | 0.15 (0.14–0.16) | 270 | 0.17 (0.16–0.19) | 203 | 0.13 (0.12–0.14) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 200 | 0.14 (0.13–0.16) |
| WHO grade IV(4) d | 282 | 0.09 (0.08–0.09) | 163 | 0.10 (0.09–0.11) | 120 | 0.07 (0.06–0.08) | — | — | 118 | 0.11 (0.10–0.13) | 162 | 0.11 (0.09–0.12) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 10 312 | 2.61 (2.57–2.64) | 6070 | 3.27 (3.21–3.33) | 4243 | 2.02 (1.98–2.07) | 96 | 0.16 (0.14–0.18) | 562 | 0.53 (0.50–0.56) | 9654 | 5.54 (5.46–5.62) |
| WHO grade II(2) d | 197 | 0.06 (0.05–0.06) | 106 | 0.06 (0.05–0.07) | 92 | 0.05 (0.04–0.06) | 17 | 0.03 (0.02–0.04) | 46 | 0.04 (0.03–0.05) | 134 | 0.08 (0.07–0.09) |
| WHO grade III(3) d | 381 | 0.10 (0.10–0.11) | 206 | 0.12 (0.11–0.13) | 176 | 0.09 (0.08–0.10) | 10 | 0.02 (0.01–0.02) | 64 | 0.06 (0.05–0.07) | 307 | 0.18 (0.17–0.20) |
| WHO grade IV(4) d | 7386 | 1.85 (1.82–1.88) | 4416 | 2.36 (2.31–2.41) | 2970 | 1.40 (1.37–1.44) | 44 | 0.07 (0.06–0.09) | 334 | 0.32 (0.29–0.34) | 7009 | 4.01 (3.94–4.08) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | 940 | 0.29 (0.28–0.31) | 518 | 0.33 (0.31–0.35) | 422 | 0.26 (0.24–0.28) | — | — | 342 | 0.32 (0.30–0.35) | 591 | 0.41 (0.38–0.43) |
| WHO grade II(2) d | 470 | 0.15 (0.14–0.16) | 257 | 0.17 (0.15–0.18) | 213 | 0.13 (0.12–0.15) | — | — | 199 | 0.19 (0.17–0.20) | 265 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 320 | 0.10 (0.09–0.10) | 180 | 0.11 (0.10–0.12) | 140 | 0.08 (0.07–0.09) | — | — | 100 | 0.09 (0.08–0.11) | 220 | 0.15 (0.13–0.16) |
| Ependymal tumors | 1382 | 0.42 (0.41–0.43) | 793 | 0.49 (0.47–0.50) | 589 | 0.35 (0.34–0.37) | 185 | 0.30 (0.28–0.32) | 385 | 0.36 (0.34–0.38) | 812 | 0.53 (0.51–0.54) |
| Spinal ependymomag | 654 | 0.20 (0.19–0.21) | 352 | 0.22 (0.21–0.23) | 302 | 0.18 (0.17–0.19) | 28 | 0.05 (0.04–0.05) | 226 | 0.21 (0.20–0.22) | 400 | 0.26 (0.25–0.28) |
| Supratentorial ependymomah | 112 | 0.04 (0.03–0.04) | 57 | 0.04 (0.03–0.04) | 55 | 0.03 (0.03–0.04) | 36 | 0.06 (0.05–0.07) | 30 | 0.03 (0.02–0.03) | 45 | 0.03 (0.03–0.03) |
| Infratentorial (posterior fossa) ependymomai | 468 | 0.14 (0.13–0.15) | 295 | 0.18 (0.17–0.19) | 173 | 0.10 (0.10–0.11) | 78 | 0.13 (0.12–0.14) | 96 | 0.09 (0.08–0.10) | 294 | 0.19 (0.18–0.20) |
| Diffuse midline glioma, H3 K27M-mutantf | 166 | 0.06 (0.05–0.06) | 75 | 0.05 (0.04–0.06) | 90 | 0.06 (0.05–0.07) | 84 | 0.14 (0.12–0.16) | 53 | 0.05 (0.04–0.06) | 29 | 0.02 (0.02–0.03) |
| High-grade glioma of the brainstemj | 547 | 0.18 (0.17–0.18) | 278 | 0.18 (0.17–0.19) | 269 | 0.18 (0.17–0.19) | 232 | 0.38 (0.36–0.41) | 141 | 0.13 (0.12–0.14) | 173 | 0.11 (0.10–0.12) |
| Meningiomas | 35 689 | 9.51 (9.46–9.55) | 9667 | 5.64 (5.59–5.69) | 26 022 | 12.95 (12.87–13.02) | 64 | 0.10 (0.09–0.12) | 2025 | 1.97 (1.93–2.01) | 33 600 | 20.41 (20.31–20.51) |
| WHO grade I(1) d | 11 934 | 3.22 (3.20–3.25) | 3224 | 1.85 (1.82–1.88) | 8710 | 4.49 (4.44–4.53) | 22 | 0.04 (0.03–0.04) | 915 | 0.90 (0.87–0.92) | 10 997 | 6.73 (6.67–6.79) |
| WHO grade II(2) d | 1975 | 0.54 (0.53–0.55) | 827 | 0.47 (0.46–0.49) | 1148 | 0.61 (0.59–0.62) | 16 | 0.03 (0.02–0.03) | 216 | 0.21 (0.19–0.22) | 1743 | 1.07 (1.05–1.09) |
| WHO grade III(3) d | 165 | 0.04 (0.04–0.05) | 84 | 0.05 (0.04–0.05) | 81 | 0.04 (0.04–0.05) | — | — | 13 | 0.01 (0.01–0.02) | 150 | 0.09 (0.08–0.10) |
| CNS lymphoma | 1696 | 0.45 (0.44–0.46) | 866 | 0.49 (0.48–0.51) | 831 | 0.41 (0.39–0.42) | 18 | 0.03 (0.02–0.04) | 106 | 0.10 (0.09–0.11) | 1572 | 0.94 (0.92–0.96) |
| Embryonal tumors | 634 | 0.22 (0.21–0.22) | 382 | 0.26 (0.25–0.27) | 252 | 0.18 (0.17–0.19) | 429 | 0.71 (0.68–0.74) | 151 | 0.14 (0.13–0.15) | 54 | 0.04 (0.03–0.04) |
| Medulloblastomak | 450 | 0.15 (0.15–0.16) | 287 | 0.19 (0.18–0.20) | 163 | 0.11 (0.11–0.12) | 293 | 0.48 (0.46–0.51) | 127 | 0.11 (0.11–0.12) | 31 | 0.02 (0.02–0.03) |
| SHH-activated and TP53-wildtype f | 80 | 0.03 (0.02–0.03) | 52 | 0.03 (0.03–0.04) | 29 | 0.02 (0.01–0.03) | 36 | 0.06 (0.05–0.08) | 38 | 0.03 (0.03–0.04) | — | — |
| SHH-activated and TP53-mutant f | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 14 | 0.01 (0.00–0.01) | — | — | 10 | 0.01 (0.00–0.01) | 12 | 0.02 (0.01–0.03) | — | — | — | — |
| Non-WNT/non-SHHf | 67 | 0.02 (0.02–0.03) | 44 | 0.03 (0.02–0.04) | 22 | 0.02 (0.01–0.02) | 55 | 0.09 (0.08–0.11) | 10 | 0.01 (0.01–0.01) | — | — |
| AT/RTl | 82 | 0.03 (0.03–0.03) | 42 | 0.03 (0.02–0.03) | 41 | 0.03 (0.02–0.03) | 73 | 0.12 (0.11–0.13) | 6 | 0.01 (0.00–0.01) | 3 | 0.00 (0.00–0.00) |
| Germ cell tumors | 256 | 0.09 (0.08–0.09) | 188 | 0.12 (0.12–0.13) | 68 | 0.05 (0.04–0.05) | 116 | 0.19 (0.18–0.21) | 125 | 0.11 (0.10–0.12) | 15 | 0.01 (0.01–0.01) |
| Cranial and paraspinal nerve tumors | 7403 | 2.05 (2.03–2.07) | 3553 | 2.05 (2.02–2.08) | 3850 | 2.06 (2.03–2.09) | 137 | 0.23 (0.21–0.24) | 1102 | 1.04 (1.02–1.07) | 6164 | 3.79 (3.74–3.83) |
| Tumors of the pituitary | 15 373 | 4.50 (4.47–4.53) | 6796 | 3.98 (3.94–4.03) | 8576 | 5.10 (5.05–5.15) | 223 | 0.37 (0.35–0.39) | 4596 | 4.26 (4.21–4.32) | 10 554 | 6.75 (6.69–6.81) |
| Histopathology (tumor type) . | Race . | Hispanic Ethnicity . | ||||||||||
| White . | Black . | AIAN . | API . | Non-Hispanic . | Hispanic . | |||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 18 735 | 6.45 (6.40–6.49) | 1569 | 3.53 (3.45–3.61) | 125 | 2.92 (2.69–3.17) | 481 | 2.33 (2.24–2.43) | 19 130 | 6.20 (6.16–6.24) | 2232 | 4.63 (4.54–4.72) |
| Glioblastoma | 11 354 | 3.55 (3.52–3.58) | 796 | 1.82 (1.76–1.88) | 59 | 1.50 (1.33–1.70) | 248 | 1.20 (1.13–1.27) | 11 566 | 3.36 (3.33–3.39) | 1086 | 2.59 (2.52–2.66) |
| Diffuse and anaplastic astrocytoma | 2565 | 0.95 (0.94–0.97) | 211 | 0.47 (0.45–0.50) | 17 | 0.37 (0.29–0.46) | 77 | 0.36 (0.33–0.40) | 2623 | 0.92 (0.91–0.94) | 313 | 0.60 (0.57–0.63) |
| WHO grade II(2) d | 775 | 0.31 (0.30–0.32) | 67 | 0.15 (0.13–0.17) | 5 | 0.11 (0.07–0.16) | 25 | 0.12 (0.10–0.14) | 794 | 0.30 (0.29–0.31) | 102 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 1224 | 0.45 (0.43–0.46) | 91 | 0.21 (0.19–0.23) | 7 | 0.17 (0.12–0.24) | 33 | 0.15 (0.13–0.18) | 1245 | 0.43 (0.41–0.44) | 137 | 0.26 (0.24–0.28) |
| Oligodendroglial tumorse | 975 | 0.39 (0.37–0.40) | 62 | 0.14 (0.13–0.16) | 12 | 0.27 (0.20–0.35) | 31 | 0.14 (0.12–0.17) | 965 | 0.36 (0.35–0.37) | 146 | 0.27 (0.25–0.30) |
| WHO grade II(2) d | 538 | 0.22 (0.21–0.23) | 32 | 0.07 (0.06–0.09) | 7 | 0.16 (0.12–0.23) | 15 | 0.07 (0.05–0.08) | 529 | 0.20 (0.20–0.21) | 79 | 0.15 (0.13–0.16) |
| WHO grade III(3) d | 326 | 0.12 (0.12–0.13) | 19 | 0.04 (0.04–0.05) | — | — | 12 | 0.06 (0.04–0.07) | 321 | 0.11 (0.11–0.12) | 48 | 0.09 (0.08–0.11) |
| Pilocytic astrocytoma | 854 | 0.38 (0.37–0.40) | 132 | 0.28 (0.26–0.30) | 10 | 0.19 (0.14–0.25) | 26 | 0.14 (0.11–0.16) | 899 | 0.40 (0.39–0.41) | 169 | 0.25 (0.23–0.26) |
| Molecularly defined adult-type diffuse glioma f | 11 278 | 3.67 (3.62–3.72) | 804 | 1.79 (1.70–1.88) | 74 | 1.72 (1.45–2.03) | 266 | 1.20 (1.10–1.31) | 11 513 | 3.50 (3.45–3.55) | 1160 | 2.44 (2.34–2.55) |
| Astrocytoma, IDH-mutant | 1250 | 0.51 (0.49–0.53) | 96 | 0.21 (0.18–0.25) | — | — | 30 | 0.13 (0.10–0.17) | 1268 | 0.49 (0.47–0.51) | 153 | 0.27 (0.24–0.30) |
| WHO grade II(2) d | 368 | 0.15 (0.14–0.17) | 27 | 0.06 (0.05–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 378 | 0.15 (0.14–0.16) | 44 | 0.08 (0.06–0.10) |
| WHO grade III(3) d | 425 | 0.18 (0.16–0.19) | 28 | 0.06 (0.05–0.08) | — | — | — | — | 421 | 0.17 (0.15–0.18) | 52 | 0.09 (0.07–0.11) |
| WHO grade IV(4)d | 242 | 0.09 (0.09–0.10) | 23 | 0.05 (0.04–0.07) | — | — | — | — | 256 | 0.09 (0.09–0.10) | 26 | 0.05 (0.04–0.06) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 9205 | 2.84 (2.79–2.88) | 662 | 1.46 (1.38–1.55) | 55 | 1.32 (1.08–1.60) | 208 | 0.94 (0.85–1.04) | 9434 | 2.71 (2.67–2.75) | 879 | 1.94 (1.84–2.03) |
| WHO grade II(2)d | 167 | 0.06 (0.05–0.07) | 18 | 0.04 (0.03–0.05) | — | — | — | — | 178 | 0.06 (0.05–0.07) | 19 | 0.04 (0.03–0.05) |
| WHO grade III(3)d | 330 | 0.11 (0.10–0.12) | 29 | 0.07 (0.05–0.09) | — | — | 10 | 0.05 (0.03–0.07) | 350 | 0.11 (0.10–0.12) | 30 | 0.06 (0.04–0.08) |
| WHO grade IV(4)d | 6609 | 2.02 (1.98–2.05) | 472 | 1.04 (0.97–1.11) | 37 | 0.90 (0.70–1.14) | 144 | 0.65 (0.58–0.74) | 6760 | 1.92 (1.89–1.95) | 626 | 1.39 (1.31–1.47) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleleted | 823 | 0.33 (0.31–0.34) | 47 | 0.11 (0.09–0.13) | 12 | 0.26 (0.17–0.39) | 29 | 0.13 (0.10–0.16) | 812 | 0.31 (0.29–0.32) | 128 | 0.24 (0.21–0.27) |
| WHO grade II(2)d | 406 | 0.17 (0.16–0.18) | 25 | 0.06 (0.04–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 402 | 0.16 (0.15–0.17) | 68 | 0.12 (0.10–0.15) |
| WHO grade III(3)d | 284 | 0.11 (0.10–0.12) | 16 | 0.04 (0.02–0.05) | — | — | 11 | 0.05 (0.03–0.07) | 278 | 0.10 (0.09–0.11) | 42 | 0.08 (0.06–0.10) |
| Ependymal tumors | 1170 | 0.45 (0.44–0.46) | 123 | 0.27 (0.25–0.30) | 11 | 0.24 (0.18–0.31) | 36 | 0.17 (0.15–0.20) | 1179 | 0.43 (0.42–0.44) | 204 | 0.36 (0.34–0.39) |
| Spinal ependymoma g | 564 | 0.22 (0.21–0.23) | 47 | 0.11 (0.09–0.12) | 5 | 0.11 (0.07–0.17) | 17 | 0.08 (0.06–0.09) | 562 | 0.21 (0.20–0.21) | 92 | 0.17 (0.15–0.18) |
| Supratentorial ependymoma | 87 | 0.04 (0.03–0.04) | 15 | 0.03 (0.03–0.04) | — | — | 5 | 0.03 (0.02–0.04) | 93 | 0.04 (0.03–0.04) | 18 | 0.03 (0.02–0.04) |
| Infratentorial ependymomai | 397 | 0.15 (0.14–0.16) | 46 | 0.10 (0.09–0.12) | — | — | 10 | 0.05 (0.04–0.07) | 401 | 0.14 (0.14–0.15) | 68 | 0.12 (0.11–0.14) |
| Diffuse midline glioma, H3 K27M-mutantf | 122 | 0.05 (0.05–0.06) | 24 | 0.05 (0.04–0.07) | — | 8 | 0.04 (0.03–0.07) | 126 | 0.06 (0.05–0.06) | 39 | 0.06 (0.05–0.07) | |
| High-grade glioma of the brainstem j | 427 | 0.18 (0.17–0.19) | 81 | 0.17 (0.16–0.19) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 454 | 0.18 (0.18–0.19) | 92 | 0.15 (0.13–0.16) |
| Meningiomas | 28 753 | 9.27 (9.22–9.32) | 4592 | 11.12 (10.97–11.27) | 219 | 5.98 (5.61–6.37) | 1359 | 6.81 (6.65–6.98) | 32 046 | 9.62 (9.57–9.66) | 3643 | 9.02 (8.88–9.15) |
| WHO grade I(1)d | 9572 | 3.16 (3.13–3.19) | 1538 | 3.62 (3.54–3.71) | 83 | 2.14 (1.93–2.37) | 466 | 2.23 (2.14–2.32) | 10 714 | 3.29 (3.26–3.32) | 1220 | 2.79 (2.71–2.86) |
| WHO grade II(2) d | 1496 | 0.50 (0.49–0.52) | 316 | 0.73 (0.69–0.77) | 12 | 0.31 (0.23–0.40) | 103 | 0.50 (0.45–0.54) | 1777 | 0.56 (0.55–0.57) | 199 | 0.44 (0.42–0.47) |
| WHO grade III(3) d | 129 | 0.04 (0.04–0.05) | 24 | 0.05 (0.04–0.07) | — | — | 10 | 0.05 (0.04–0.06) | 145 | 0.04 (0.04–0.05) | 20 | 0.05 (0.04–0.06) |
| CNS lymphoma | 1417 | 0.45 (0.43–0.46) | 135 | 0.31 (0.29–0.34) | 11 | 0.30 (0.23–0.40) | 95 | 0.47 (0.43–0.51) | 1485 | 0.44 (0.43–0.45) | 211 | 0.51 (0.48–0.54) |
| Embryonal tumors | 503 | 0.23 (0.22–0.24) | 74 | 0.15 (0.14–0.17) | 7 | 0.14 (0.10–0.20) | 24 | 0.13 (0.11–0.16) | 491 | 0.22 (0.21–0.23) | 143 | 0.21 (0.19–0.23) |
| Medulloblastoma k | 359 | 0.16 (0.16–0.17) | 49 | 0.10 (0.09–0.12) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 347 | 0.16 (0.15–0.16) | 104 | 0.15 (0.14–0.17) |
| SHH-activated and TP53-wildtypef | 60 | 0.03 (0.02–0.03) | 10 | 0.02 (0.01–0.03) | — | — | — | — | 62 | 0.03 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| SHH-activated and TP53-mutantf | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 11 | 0.01 (0.00–0.01) | — | — | — | — | — | — | 12 | 0.01 (0.00–0.01) | — | — |
| Non-WNT/non-SHHf | 58 | 0.03 (0.02–0.03) | — | — | — | — | — | — | 48 | 0.02 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| AT/RTl | 63 | 0.03 (0.03–0.03) | 12 | 0.02 (0.02–0.03) | — | — | 4 | 0.02 (0.02–0.04) | 64 | 0.03 (0.03–0.03) | 18 | 0.03 (0.02–0.03) |
| Germ cell tumors | 192 | 0.09 (0.08–0.09) | 30 | 0.06 (0.05–0.07) | — | — | 22 | 0.11 (0.09–0.14) | 199 | 0.09 (0.08–0.09) | 57 | 0.08 (0.07–0.09) |
| Cranial and paraspinal nerve tumors | 6253 | 2.15 (2.12–2.17) | 463 | 1.05 (1.01–1.09) | 48 | 1.14 (1.00–1.30) | 383 | 1.78 (1.70–1.87) | 6699 | 2.15 (2.13–2.18) | 704 | 1.45 (1.40–1.50) |
| Tumors of the pituitary | 10 941 | 4.05 (4.01–4.09) | 3079 | 7.10 (6.98–7.21) | 143 | 3.37 (3.11–3.63) | 648 | 3.04 (2.93–3.15) | 12 755 | 4.39 (4.35–4.43) | 2618 | 5.15 (5.06–5.24) |
| Histopathology (tumor type) . | Total . | Sex . | Age at diagnosis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male . | Female . | 0–14 years . | 15–39 years . | 40+ Years . | ||||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR 95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 21 362 | 5.94 (5.91–5.98) | 12 104 | 7.05 (6.99–7.10) | 9258 | 4.97 (4.92–5.02) | 1795 | 2.96 (2.90–3.02) | 3170 | 2.95 (2.91–3.00) | 16 397 | 9.90 (9.83–9.97) |
| Glioblastoma | 12 652 | 3.26 (3.24–3.29) | 7365 | 4.08 (4.04–4.12) | 5286 | 2.55 (2.52–2.59) | 93 | 0.15 (0.14–0.17) | 608 | 0.58 (0.56–0.60) | 11 951 | 7.03 (6.97–7.09) |
| Diffuse and anaplastic astrocytoma | 2936 | 0.87 (0.85–0.88) | 1623 | 0.98 (0.96–1.01) | 1313 | 0.75 (0.74–0.77) | 170 | 0.28 (0.26–0.30) | 932 | 0.86 (0.83–0.88) | 1834 | 1.16 (1.14–1.19) |
| WHO grade II(2)d | 896 | 0.28 (0.27–0.28) | 510 | 0.32 (0.31–0.33) | 386 | 0.23 (0.22–0.25) | 49 | 0.08 (0.07–0.09) | 388 | 0.36 (0.34–0.37) | 459 | 0.30 (0.29–0.32) |
| WHO grade III(3)d | 1382 | 0.40 (0.39–0.41) | 764 | 0.46 (0.44–0.47) | 618 | 0.35 (0.33–0.36) | 38 | 0.06 (0.05–0.07) | 406 | 0.37 (0.36–0.39) | 939 | 0.59 (0.57–0.61) |
Oligodendroglial tumorse | 1112 | 0.34 (0.33–0.35) | 615 | 0.39 (0.37–0.40) | 497 | 0.30 (0.29–0.31) | 15 | 0.02 (0.02–0.03) | 389 | 0.37 (0.35–0.38) | 708 | 0.48 (0.47–0.50) |
| WHO grade II(2)d | 608 | 0.19 (0.19–0.20) | 333 | 0.21 (0.20–0.22) | 276 | 0.17 (0.16–0.18) | 7 | 0.01 (0.01–0.02) | 244 | 0.23 (0.22–0.24) | 357 | 0.25 (0.24–0.27) |
| WHO grade III(3)d | 369 | 0.11 (0.11–0.12) | 204 | 0.13 (0.12–0.13) | 164 | 0.10 (0.09–0.10) | — | — | 104 | 0.10 (0.09–0.11) | 263 | 0.18 (0.17–0.19) |
| Pilocytic astrocytoma | 1068 | 0.36 (0.35–0.37) | 561 | 0.38 (0.36–0.39) | 507 | 0.35 (0.34–0.36) | 657 | 1.08 (1.04–1.12) | 293 | 0.27 (0.26–0.28) | 119 | 0.08 (0.07–0.09) |
| Molecularly-defined adult-type diffuse gliomaf | 12 674 | 3.34 (3.30–3.38) | 7400 | 4.11 (4.04–4.18) | 5273 | 2.66 (2.60–2.71) | 136 | 0.23 (0.20–0.26) | 1643 | 1.53 (1.47–1.58) | 10 894 | 6.39 (6.31–6.48) |
| Astrocytoma, IDH-mutant | 1421 | 0.44 (0.43–0.46) | 814 | 0.51 (0.49–0.54) | 608 | 0.38 (0.35–0.40) | 33 | 0.05 (0.04–0.07) | 740 | 0.68 (0.64–0.71) | 648 | 0.45 (0.42–0.47) |
| WHO grade II(2) d | 422 | 0.14 (0.13–0.15) | 248 | 0.16 (0.15–0.17) | 175 | 0.11 (0.10–0.13) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 149 | 0.11 (0.10–0.12) |
| WHO grade III(3) d | 474 | 0.15 (0.14–0.16) | 270 | 0.17 (0.16–0.19) | 203 | 0.13 (0.12–0.14) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 200 | 0.14 (0.13–0.16) |
| WHO grade IV(4) d | 282 | 0.09 (0.08–0.09) | 163 | 0.10 (0.09–0.11) | 120 | 0.07 (0.06–0.08) | — | — | 118 | 0.11 (0.10–0.13) | 162 | 0.11 (0.09–0.12) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 10 312 | 2.61 (2.57–2.64) | 6070 | 3.27 (3.21–3.33) | 4243 | 2.02 (1.98–2.07) | 96 | 0.16 (0.14–0.18) | 562 | 0.53 (0.50–0.56) | 9654 | 5.54 (5.46–5.62) |
| WHO grade II(2) d | 197 | 0.06 (0.05–0.06) | 106 | 0.06 (0.05–0.07) | 92 | 0.05 (0.04–0.06) | 17 | 0.03 (0.02–0.04) | 46 | 0.04 (0.03–0.05) | 134 | 0.08 (0.07–0.09) |
| WHO grade III(3) d | 381 | 0.10 (0.10–0.11) | 206 | 0.12 (0.11–0.13) | 176 | 0.09 (0.08–0.10) | 10 | 0.02 (0.01–0.02) | 64 | 0.06 (0.05–0.07) | 307 | 0.18 (0.17–0.20) |
| WHO grade IV(4) d | 7386 | 1.85 (1.82–1.88) | 4416 | 2.36 (2.31–2.41) | 2970 | 1.40 (1.37–1.44) | 44 | 0.07 (0.06–0.09) | 334 | 0.32 (0.29–0.34) | 7009 | 4.01 (3.94–4.08) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | 940 | 0.29 (0.28–0.31) | 518 | 0.33 (0.31–0.35) | 422 | 0.26 (0.24–0.28) | — | — | 342 | 0.32 (0.30–0.35) | 591 | 0.41 (0.38–0.43) |
| WHO grade II(2) d | 470 | 0.15 (0.14–0.16) | 257 | 0.17 (0.15–0.18) | 213 | 0.13 (0.12–0.15) | — | — | 199 | 0.19 (0.17–0.20) | 265 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 320 | 0.10 (0.09–0.10) | 180 | 0.11 (0.10–0.12) | 140 | 0.08 (0.07–0.09) | — | — | 100 | 0.09 (0.08–0.11) | 220 | 0.15 (0.13–0.16) |
| Ependymal tumors | 1382 | 0.42 (0.41–0.43) | 793 | 0.49 (0.47–0.50) | 589 | 0.35 (0.34–0.37) | 185 | 0.30 (0.28–0.32) | 385 | 0.36 (0.34–0.38) | 812 | 0.53 (0.51–0.54) |
| Spinal ependymomag | 654 | 0.20 (0.19–0.21) | 352 | 0.22 (0.21–0.23) | 302 | 0.18 (0.17–0.19) | 28 | 0.05 (0.04–0.05) | 226 | 0.21 (0.20–0.22) | 400 | 0.26 (0.25–0.28) |
| Supratentorial ependymomah | 112 | 0.04 (0.03–0.04) | 57 | 0.04 (0.03–0.04) | 55 | 0.03 (0.03–0.04) | 36 | 0.06 (0.05–0.07) | 30 | 0.03 (0.02–0.03) | 45 | 0.03 (0.03–0.03) |
| Infratentorial (posterior fossa) ependymomai | 468 | 0.14 (0.13–0.15) | 295 | 0.18 (0.17–0.19) | 173 | 0.10 (0.10–0.11) | 78 | 0.13 (0.12–0.14) | 96 | 0.09 (0.08–0.10) | 294 | 0.19 (0.18–0.20) |
| Diffuse midline glioma, H3 K27M-mutantf | 166 | 0.06 (0.05–0.06) | 75 | 0.05 (0.04–0.06) | 90 | 0.06 (0.05–0.07) | 84 | 0.14 (0.12–0.16) | 53 | 0.05 (0.04–0.06) | 29 | 0.02 (0.02–0.03) |
| High-grade glioma of the brainstemj | 547 | 0.18 (0.17–0.18) | 278 | 0.18 (0.17–0.19) | 269 | 0.18 (0.17–0.19) | 232 | 0.38 (0.36–0.41) | 141 | 0.13 (0.12–0.14) | 173 | 0.11 (0.10–0.12) |
| Meningiomas | 35 689 | 9.51 (9.46–9.55) | 9667 | 5.64 (5.59–5.69) | 26 022 | 12.95 (12.87–13.02) | 64 | 0.10 (0.09–0.12) | 2025 | 1.97 (1.93–2.01) | 33 600 | 20.41 (20.31–20.51) |
| WHO grade I(1) d | 11 934 | 3.22 (3.20–3.25) | 3224 | 1.85 (1.82–1.88) | 8710 | 4.49 (4.44–4.53) | 22 | 0.04 (0.03–0.04) | 915 | 0.90 (0.87–0.92) | 10 997 | 6.73 (6.67–6.79) |
| WHO grade II(2) d | 1975 | 0.54 (0.53–0.55) | 827 | 0.47 (0.46–0.49) | 1148 | 0.61 (0.59–0.62) | 16 | 0.03 (0.02–0.03) | 216 | 0.21 (0.19–0.22) | 1743 | 1.07 (1.05–1.09) |
| WHO grade III(3) d | 165 | 0.04 (0.04–0.05) | 84 | 0.05 (0.04–0.05) | 81 | 0.04 (0.04–0.05) | — | — | 13 | 0.01 (0.01–0.02) | 150 | 0.09 (0.08–0.10) |
| CNS lymphoma | 1696 | 0.45 (0.44–0.46) | 866 | 0.49 (0.48–0.51) | 831 | 0.41 (0.39–0.42) | 18 | 0.03 (0.02–0.04) | 106 | 0.10 (0.09–0.11) | 1572 | 0.94 (0.92–0.96) |
| Embryonal tumors | 634 | 0.22 (0.21–0.22) | 382 | 0.26 (0.25–0.27) | 252 | 0.18 (0.17–0.19) | 429 | 0.71 (0.68–0.74) | 151 | 0.14 (0.13–0.15) | 54 | 0.04 (0.03–0.04) |
| Medulloblastomak | 450 | 0.15 (0.15–0.16) | 287 | 0.19 (0.18–0.20) | 163 | 0.11 (0.11–0.12) | 293 | 0.48 (0.46–0.51) | 127 | 0.11 (0.11–0.12) | 31 | 0.02 (0.02–0.03) |
| SHH-activated and TP53-wildtype f | 80 | 0.03 (0.02–0.03) | 52 | 0.03 (0.03–0.04) | 29 | 0.02 (0.01–0.03) | 36 | 0.06 (0.05–0.08) | 38 | 0.03 (0.03–0.04) | — | — |
| SHH-activated and TP53-mutant f | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 14 | 0.01 (0.00–0.01) | — | — | 10 | 0.01 (0.00–0.01) | 12 | 0.02 (0.01–0.03) | — | — | — | — |
| Non-WNT/non-SHHf | 67 | 0.02 (0.02–0.03) | 44 | 0.03 (0.02–0.04) | 22 | 0.02 (0.01–0.02) | 55 | 0.09 (0.08–0.11) | 10 | 0.01 (0.01–0.01) | — | — |
| AT/RTl | 82 | 0.03 (0.03–0.03) | 42 | 0.03 (0.02–0.03) | 41 | 0.03 (0.02–0.03) | 73 | 0.12 (0.11–0.13) | 6 | 0.01 (0.00–0.01) | 3 | 0.00 (0.00–0.00) |
| Germ cell tumors | 256 | 0.09 (0.08–0.09) | 188 | 0.12 (0.12–0.13) | 68 | 0.05 (0.04–0.05) | 116 | 0.19 (0.18–0.21) | 125 | 0.11 (0.10–0.12) | 15 | 0.01 (0.01–0.01) |
| Cranial and paraspinal nerve tumors | 7403 | 2.05 (2.03–2.07) | 3553 | 2.05 (2.02–2.08) | 3850 | 2.06 (2.03–2.09) | 137 | 0.23 (0.21–0.24) | 1102 | 1.04 (1.02–1.07) | 6164 | 3.79 (3.74–3.83) |
| Tumors of the pituitary | 15 373 | 4.50 (4.47–4.53) | 6796 | 3.98 (3.94–4.03) | 8576 | 5.10 (5.05–5.15) | 223 | 0.37 (0.35–0.39) | 4596 | 4.26 (4.21–4.32) | 10 554 | 6.75 (6.69–6.81) |
| Histopathology (tumor type) . | Race . | Hispanic Ethnicity . | ||||||||||
| White . | Black . | AIAN . | API . | Non-Hispanic . | Hispanic . | |||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 18 735 | 6.45 (6.40–6.49) | 1569 | 3.53 (3.45–3.61) | 125 | 2.92 (2.69–3.17) | 481 | 2.33 (2.24–2.43) | 19 130 | 6.20 (6.16–6.24) | 2232 | 4.63 (4.54–4.72) |
| Glioblastoma | 11 354 | 3.55 (3.52–3.58) | 796 | 1.82 (1.76–1.88) | 59 | 1.50 (1.33–1.70) | 248 | 1.20 (1.13–1.27) | 11 566 | 3.36 (3.33–3.39) | 1086 | 2.59 (2.52–2.66) |
| Diffuse and anaplastic astrocytoma | 2565 | 0.95 (0.94–0.97) | 211 | 0.47 (0.45–0.50) | 17 | 0.37 (0.29–0.46) | 77 | 0.36 (0.33–0.40) | 2623 | 0.92 (0.91–0.94) | 313 | 0.60 (0.57–0.63) |
| WHO grade II(2) d | 775 | 0.31 (0.30–0.32) | 67 | 0.15 (0.13–0.17) | 5 | 0.11 (0.07–0.16) | 25 | 0.12 (0.10–0.14) | 794 | 0.30 (0.29–0.31) | 102 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 1224 | 0.45 (0.43–0.46) | 91 | 0.21 (0.19–0.23) | 7 | 0.17 (0.12–0.24) | 33 | 0.15 (0.13–0.18) | 1245 | 0.43 (0.41–0.44) | 137 | 0.26 (0.24–0.28) |
| Oligodendroglial tumorse | 975 | 0.39 (0.37–0.40) | 62 | 0.14 (0.13–0.16) | 12 | 0.27 (0.20–0.35) | 31 | 0.14 (0.12–0.17) | 965 | 0.36 (0.35–0.37) | 146 | 0.27 (0.25–0.30) |
| WHO grade II(2) d | 538 | 0.22 (0.21–0.23) | 32 | 0.07 (0.06–0.09) | 7 | 0.16 (0.12–0.23) | 15 | 0.07 (0.05–0.08) | 529 | 0.20 (0.20–0.21) | 79 | 0.15 (0.13–0.16) |
| WHO grade III(3) d | 326 | 0.12 (0.12–0.13) | 19 | 0.04 (0.04–0.05) | — | — | 12 | 0.06 (0.04–0.07) | 321 | 0.11 (0.11–0.12) | 48 | 0.09 (0.08–0.11) |
| Pilocytic astrocytoma | 854 | 0.38 (0.37–0.40) | 132 | 0.28 (0.26–0.30) | 10 | 0.19 (0.14–0.25) | 26 | 0.14 (0.11–0.16) | 899 | 0.40 (0.39–0.41) | 169 | 0.25 (0.23–0.26) |
| Molecularly defined adult-type diffuse glioma f | 11 278 | 3.67 (3.62–3.72) | 804 | 1.79 (1.70–1.88) | 74 | 1.72 (1.45–2.03) | 266 | 1.20 (1.10–1.31) | 11 513 | 3.50 (3.45–3.55) | 1160 | 2.44 (2.34–2.55) |
| Astrocytoma, IDH-mutant | 1250 | 0.51 (0.49–0.53) | 96 | 0.21 (0.18–0.25) | — | — | 30 | 0.13 (0.10–0.17) | 1268 | 0.49 (0.47–0.51) | 153 | 0.27 (0.24–0.30) |
| WHO grade II(2) d | 368 | 0.15 (0.14–0.17) | 27 | 0.06 (0.05–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 378 | 0.15 (0.14–0.16) | 44 | 0.08 (0.06–0.10) |
| WHO grade III(3) d | 425 | 0.18 (0.16–0.19) | 28 | 0.06 (0.05–0.08) | — | — | — | — | 421 | 0.17 (0.15–0.18) | 52 | 0.09 (0.07–0.11) |
| WHO grade IV(4)d | 242 | 0.09 (0.09–0.10) | 23 | 0.05 (0.04–0.07) | — | — | — | — | 256 | 0.09 (0.09–0.10) | 26 | 0.05 (0.04–0.06) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 9205 | 2.84 (2.79–2.88) | 662 | 1.46 (1.38–1.55) | 55 | 1.32 (1.08–1.60) | 208 | 0.94 (0.85–1.04) | 9434 | 2.71 (2.67–2.75) | 879 | 1.94 (1.84–2.03) |
| WHO grade II(2)d | 167 | 0.06 (0.05–0.07) | 18 | 0.04 (0.03–0.05) | — | — | — | — | 178 | 0.06 (0.05–0.07) | 19 | 0.04 (0.03–0.05) |
| WHO grade III(3)d | 330 | 0.11 (0.10–0.12) | 29 | 0.07 (0.05–0.09) | — | — | 10 | 0.05 (0.03–0.07) | 350 | 0.11 (0.10–0.12) | 30 | 0.06 (0.04–0.08) |
| WHO grade IV(4)d | 6609 | 2.02 (1.98–2.05) | 472 | 1.04 (0.97–1.11) | 37 | 0.90 (0.70–1.14) | 144 | 0.65 (0.58–0.74) | 6760 | 1.92 (1.89–1.95) | 626 | 1.39 (1.31–1.47) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleleted | 823 | 0.33 (0.31–0.34) | 47 | 0.11 (0.09–0.13) | 12 | 0.26 (0.17–0.39) | 29 | 0.13 (0.10–0.16) | 812 | 0.31 (0.29–0.32) | 128 | 0.24 (0.21–0.27) |
| WHO grade II(2)d | 406 | 0.17 (0.16–0.18) | 25 | 0.06 (0.04–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 402 | 0.16 (0.15–0.17) | 68 | 0.12 (0.10–0.15) |
| WHO grade III(3)d | 284 | 0.11 (0.10–0.12) | 16 | 0.04 (0.02–0.05) | — | — | 11 | 0.05 (0.03–0.07) | 278 | 0.10 (0.09–0.11) | 42 | 0.08 (0.06–0.10) |
| Ependymal tumors | 1170 | 0.45 (0.44–0.46) | 123 | 0.27 (0.25–0.30) | 11 | 0.24 (0.18–0.31) | 36 | 0.17 (0.15–0.20) | 1179 | 0.43 (0.42–0.44) | 204 | 0.36 (0.34–0.39) |
| Spinal ependymoma g | 564 | 0.22 (0.21–0.23) | 47 | 0.11 (0.09–0.12) | 5 | 0.11 (0.07–0.17) | 17 | 0.08 (0.06–0.09) | 562 | 0.21 (0.20–0.21) | 92 | 0.17 (0.15–0.18) |
| Supratentorial ependymoma | 87 | 0.04 (0.03–0.04) | 15 | 0.03 (0.03–0.04) | — | — | 5 | 0.03 (0.02–0.04) | 93 | 0.04 (0.03–0.04) | 18 | 0.03 (0.02–0.04) |
| Infratentorial ependymomai | 397 | 0.15 (0.14–0.16) | 46 | 0.10 (0.09–0.12) | — | — | 10 | 0.05 (0.04–0.07) | 401 | 0.14 (0.14–0.15) | 68 | 0.12 (0.11–0.14) |
| Diffuse midline glioma, H3 K27M-mutantf | 122 | 0.05 (0.05–0.06) | 24 | 0.05 (0.04–0.07) | — | 8 | 0.04 (0.03–0.07) | 126 | 0.06 (0.05–0.06) | 39 | 0.06 (0.05–0.07) | |
| High-grade glioma of the brainstem j | 427 | 0.18 (0.17–0.19) | 81 | 0.17 (0.16–0.19) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 454 | 0.18 (0.18–0.19) | 92 | 0.15 (0.13–0.16) |
| Meningiomas | 28 753 | 9.27 (9.22–9.32) | 4592 | 11.12 (10.97–11.27) | 219 | 5.98 (5.61–6.37) | 1359 | 6.81 (6.65–6.98) | 32 046 | 9.62 (9.57–9.66) | 3643 | 9.02 (8.88–9.15) |
| WHO grade I(1)d | 9572 | 3.16 (3.13–3.19) | 1538 | 3.62 (3.54–3.71) | 83 | 2.14 (1.93–2.37) | 466 | 2.23 (2.14–2.32) | 10 714 | 3.29 (3.26–3.32) | 1220 | 2.79 (2.71–2.86) |
| WHO grade II(2) d | 1496 | 0.50 (0.49–0.52) | 316 | 0.73 (0.69–0.77) | 12 | 0.31 (0.23–0.40) | 103 | 0.50 (0.45–0.54) | 1777 | 0.56 (0.55–0.57) | 199 | 0.44 (0.42–0.47) |
| WHO grade III(3) d | 129 | 0.04 (0.04–0.05) | 24 | 0.05 (0.04–0.07) | — | — | 10 | 0.05 (0.04–0.06) | 145 | 0.04 (0.04–0.05) | 20 | 0.05 (0.04–0.06) |
| CNS lymphoma | 1417 | 0.45 (0.43–0.46) | 135 | 0.31 (0.29–0.34) | 11 | 0.30 (0.23–0.40) | 95 | 0.47 (0.43–0.51) | 1485 | 0.44 (0.43–0.45) | 211 | 0.51 (0.48–0.54) |
| Embryonal tumors | 503 | 0.23 (0.22–0.24) | 74 | 0.15 (0.14–0.17) | 7 | 0.14 (0.10–0.20) | 24 | 0.13 (0.11–0.16) | 491 | 0.22 (0.21–0.23) | 143 | 0.21 (0.19–0.23) |
| Medulloblastoma k | 359 | 0.16 (0.16–0.17) | 49 | 0.10 (0.09–0.12) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 347 | 0.16 (0.15–0.16) | 104 | 0.15 (0.14–0.17) |
| SHH-activated and TP53-wildtypef | 60 | 0.03 (0.02–0.03) | 10 | 0.02 (0.01–0.03) | — | — | — | — | 62 | 0.03 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| SHH-activated and TP53-mutantf | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 11 | 0.01 (0.00–0.01) | — | — | — | — | — | — | 12 | 0.01 (0.00–0.01) | — | — |
| Non-WNT/non-SHHf | 58 | 0.03 (0.02–0.03) | — | — | — | — | — | — | 48 | 0.02 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| AT/RTl | 63 | 0.03 (0.03–0.03) | 12 | 0.02 (0.02–0.03) | — | — | 4 | 0.02 (0.02–0.04) | 64 | 0.03 (0.03–0.03) | 18 | 0.03 (0.02–0.03) |
| Germ cell tumors | 192 | 0.09 (0.08–0.09) | 30 | 0.06 (0.05–0.07) | — | — | 22 | 0.11 (0.09–0.14) | 199 | 0.09 (0.08–0.09) | 57 | 0.08 (0.07–0.09) |
| Cranial and paraspinal nerve tumors | 6253 | 2.15 (2.12–2.17) | 463 | 1.05 (1.01–1.09) | 48 | 1.14 (1.00–1.30) | 383 | 1.78 (1.70–1.87) | 6699 | 2.15 (2.13–2.18) | 704 | 1.45 (1.40–1.50) |
| Tumors of the pituitary | 10 941 | 4.05 (4.01–4.09) | 3079 | 7.10 (6.98–7.21) | 143 | 3.37 (3.11–3.63) | 648 | 3.04 (2.93–3.15) | 12 755 | 4.39 (4.35–4.43) | 2618 | 5.15 (5.06–5.24) |
aAnnual average cases are calculated by dividing the 5-year total by five.
bRates are per 100 000 and are age-adjusted to the 2000 US standard population.
cICD-O-3 histopathology codes 9380-9384, 9391-9460.
dMay not sum to total of all cases in histopathology (tumor type) due to missing grade information.
eIncludes “diffuse” oligodendroglioma and “anaplastic” oligodendroglioma.
fHistopathologies collected beginning in 2018 and onward, average annual totals and incidence rates are based on two years of cases only. Limited to cases with histopathologic confirmation only.
gIncludes ependymal tumors occurring in sites spine and cauda equina.
hIncludes ependymal tumors occurring in sites cerebellum, frontal lobe, occipital lobe, temporal love, and parietal lobe.
iIncludes ependymal tumors occurring in sites cerebrum, ventricle, and brain stem.
jDefined as high grade glioma (ICD-O-3 histopathology codes: 9380, 9381, 9400, 9401, 9440, 9441, 9442/3, 9451, and 9460) occurring in the brain stem (ICD-O-3 site code: C71.7). See Ostrom, et al.(1) Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS Statistical Report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. 24: iii1–iii38. doi: 10.1093/neuonc/noac161 for more information.
kICD-O-3 code 9470–9472, 9474–9477.
lICD-O-3 code 9508/3.
—Counts and rates are not presented when fewer than 16 cases were reported for the specific category for the 5-year period. The suppressed cases are included in the counts and rates for totals.
Abbreviations: AIAN, American Indian/Alaska Native; API, Asian or Pacific Islander; ATRT, Atypical teratoid/rhabdoid tumors; CBTRUS, Central Brain Tumor Registry of the United States; CI, confidence interval; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; SHH: Sonic Hedgehog; WNT: Wingless.
Annual average total casesa and average annual age-adjusted incidence ratesb with 95% confidence intervals for selected histopathologies (tumor types) for brain and other central nervous system tumors by grade, sex, age group at diagnosis, race, and hispanic ethnicity. (CBTRUS: Data provided by CDC’s NPCR and NCI’s SEER Program, 2015–2019)
| Histopathology (tumor type) . | Total . | Sex . | Age at diagnosis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male . | Female . | 0–14 years . | 15–39 years . | 40+ Years . | ||||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR 95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 21 362 | 5.94 (5.91–5.98) | 12 104 | 7.05 (6.99–7.10) | 9258 | 4.97 (4.92–5.02) | 1795 | 2.96 (2.90–3.02) | 3170 | 2.95 (2.91–3.00) | 16 397 | 9.90 (9.83–9.97) |
| Glioblastoma | 12 652 | 3.26 (3.24–3.29) | 7365 | 4.08 (4.04–4.12) | 5286 | 2.55 (2.52–2.59) | 93 | 0.15 (0.14–0.17) | 608 | 0.58 (0.56–0.60) | 11 951 | 7.03 (6.97–7.09) |
| Diffuse and anaplastic astrocytoma | 2936 | 0.87 (0.85–0.88) | 1623 | 0.98 (0.96–1.01) | 1313 | 0.75 (0.74–0.77) | 170 | 0.28 (0.26–0.30) | 932 | 0.86 (0.83–0.88) | 1834 | 1.16 (1.14–1.19) |
| WHO grade II(2)d | 896 | 0.28 (0.27–0.28) | 510 | 0.32 (0.31–0.33) | 386 | 0.23 (0.22–0.25) | 49 | 0.08 (0.07–0.09) | 388 | 0.36 (0.34–0.37) | 459 | 0.30 (0.29–0.32) |
| WHO grade III(3)d | 1382 | 0.40 (0.39–0.41) | 764 | 0.46 (0.44–0.47) | 618 | 0.35 (0.33–0.36) | 38 | 0.06 (0.05–0.07) | 406 | 0.37 (0.36–0.39) | 939 | 0.59 (0.57–0.61) |
Oligodendroglial tumorse | 1112 | 0.34 (0.33–0.35) | 615 | 0.39 (0.37–0.40) | 497 | 0.30 (0.29–0.31) | 15 | 0.02 (0.02–0.03) | 389 | 0.37 (0.35–0.38) | 708 | 0.48 (0.47–0.50) |
| WHO grade II(2)d | 608 | 0.19 (0.19–0.20) | 333 | 0.21 (0.20–0.22) | 276 | 0.17 (0.16–0.18) | 7 | 0.01 (0.01–0.02) | 244 | 0.23 (0.22–0.24) | 357 | 0.25 (0.24–0.27) |
| WHO grade III(3)d | 369 | 0.11 (0.11–0.12) | 204 | 0.13 (0.12–0.13) | 164 | 0.10 (0.09–0.10) | — | — | 104 | 0.10 (0.09–0.11) | 263 | 0.18 (0.17–0.19) |
| Pilocytic astrocytoma | 1068 | 0.36 (0.35–0.37) | 561 | 0.38 (0.36–0.39) | 507 | 0.35 (0.34–0.36) | 657 | 1.08 (1.04–1.12) | 293 | 0.27 (0.26–0.28) | 119 | 0.08 (0.07–0.09) |
| Molecularly-defined adult-type diffuse gliomaf | 12 674 | 3.34 (3.30–3.38) | 7400 | 4.11 (4.04–4.18) | 5273 | 2.66 (2.60–2.71) | 136 | 0.23 (0.20–0.26) | 1643 | 1.53 (1.47–1.58) | 10 894 | 6.39 (6.31–6.48) |
| Astrocytoma, IDH-mutant | 1421 | 0.44 (0.43–0.46) | 814 | 0.51 (0.49–0.54) | 608 | 0.38 (0.35–0.40) | 33 | 0.05 (0.04–0.07) | 740 | 0.68 (0.64–0.71) | 648 | 0.45 (0.42–0.47) |
| WHO grade II(2) d | 422 | 0.14 (0.13–0.15) | 248 | 0.16 (0.15–0.17) | 175 | 0.11 (0.10–0.13) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 149 | 0.11 (0.10–0.12) |
| WHO grade III(3) d | 474 | 0.15 (0.14–0.16) | 270 | 0.17 (0.16–0.19) | 203 | 0.13 (0.12–0.14) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 200 | 0.14 (0.13–0.16) |
| WHO grade IV(4) d | 282 | 0.09 (0.08–0.09) | 163 | 0.10 (0.09–0.11) | 120 | 0.07 (0.06–0.08) | — | — | 118 | 0.11 (0.10–0.13) | 162 | 0.11 (0.09–0.12) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 10 312 | 2.61 (2.57–2.64) | 6070 | 3.27 (3.21–3.33) | 4243 | 2.02 (1.98–2.07) | 96 | 0.16 (0.14–0.18) | 562 | 0.53 (0.50–0.56) | 9654 | 5.54 (5.46–5.62) |
| WHO grade II(2) d | 197 | 0.06 (0.05–0.06) | 106 | 0.06 (0.05–0.07) | 92 | 0.05 (0.04–0.06) | 17 | 0.03 (0.02–0.04) | 46 | 0.04 (0.03–0.05) | 134 | 0.08 (0.07–0.09) |
| WHO grade III(3) d | 381 | 0.10 (0.10–0.11) | 206 | 0.12 (0.11–0.13) | 176 | 0.09 (0.08–0.10) | 10 | 0.02 (0.01–0.02) | 64 | 0.06 (0.05–0.07) | 307 | 0.18 (0.17–0.20) |
| WHO grade IV(4) d | 7386 | 1.85 (1.82–1.88) | 4416 | 2.36 (2.31–2.41) | 2970 | 1.40 (1.37–1.44) | 44 | 0.07 (0.06–0.09) | 334 | 0.32 (0.29–0.34) | 7009 | 4.01 (3.94–4.08) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | 940 | 0.29 (0.28–0.31) | 518 | 0.33 (0.31–0.35) | 422 | 0.26 (0.24–0.28) | — | — | 342 | 0.32 (0.30–0.35) | 591 | 0.41 (0.38–0.43) |
| WHO grade II(2) d | 470 | 0.15 (0.14–0.16) | 257 | 0.17 (0.15–0.18) | 213 | 0.13 (0.12–0.15) | — | — | 199 | 0.19 (0.17–0.20) | 265 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 320 | 0.10 (0.09–0.10) | 180 | 0.11 (0.10–0.12) | 140 | 0.08 (0.07–0.09) | — | — | 100 | 0.09 (0.08–0.11) | 220 | 0.15 (0.13–0.16) |
| Ependymal tumors | 1382 | 0.42 (0.41–0.43) | 793 | 0.49 (0.47–0.50) | 589 | 0.35 (0.34–0.37) | 185 | 0.30 (0.28–0.32) | 385 | 0.36 (0.34–0.38) | 812 | 0.53 (0.51–0.54) |
| Spinal ependymomag | 654 | 0.20 (0.19–0.21) | 352 | 0.22 (0.21–0.23) | 302 | 0.18 (0.17–0.19) | 28 | 0.05 (0.04–0.05) | 226 | 0.21 (0.20–0.22) | 400 | 0.26 (0.25–0.28) |
| Supratentorial ependymomah | 112 | 0.04 (0.03–0.04) | 57 | 0.04 (0.03–0.04) | 55 | 0.03 (0.03–0.04) | 36 | 0.06 (0.05–0.07) | 30 | 0.03 (0.02–0.03) | 45 | 0.03 (0.03–0.03) |
| Infratentorial (posterior fossa) ependymomai | 468 | 0.14 (0.13–0.15) | 295 | 0.18 (0.17–0.19) | 173 | 0.10 (0.10–0.11) | 78 | 0.13 (0.12–0.14) | 96 | 0.09 (0.08–0.10) | 294 | 0.19 (0.18–0.20) |
| Diffuse midline glioma, H3 K27M-mutantf | 166 | 0.06 (0.05–0.06) | 75 | 0.05 (0.04–0.06) | 90 | 0.06 (0.05–0.07) | 84 | 0.14 (0.12–0.16) | 53 | 0.05 (0.04–0.06) | 29 | 0.02 (0.02–0.03) |
| High-grade glioma of the brainstemj | 547 | 0.18 (0.17–0.18) | 278 | 0.18 (0.17–0.19) | 269 | 0.18 (0.17–0.19) | 232 | 0.38 (0.36–0.41) | 141 | 0.13 (0.12–0.14) | 173 | 0.11 (0.10–0.12) |
| Meningiomas | 35 689 | 9.51 (9.46–9.55) | 9667 | 5.64 (5.59–5.69) | 26 022 | 12.95 (12.87–13.02) | 64 | 0.10 (0.09–0.12) | 2025 | 1.97 (1.93–2.01) | 33 600 | 20.41 (20.31–20.51) |
| WHO grade I(1) d | 11 934 | 3.22 (3.20–3.25) | 3224 | 1.85 (1.82–1.88) | 8710 | 4.49 (4.44–4.53) | 22 | 0.04 (0.03–0.04) | 915 | 0.90 (0.87–0.92) | 10 997 | 6.73 (6.67–6.79) |
| WHO grade II(2) d | 1975 | 0.54 (0.53–0.55) | 827 | 0.47 (0.46–0.49) | 1148 | 0.61 (0.59–0.62) | 16 | 0.03 (0.02–0.03) | 216 | 0.21 (0.19–0.22) | 1743 | 1.07 (1.05–1.09) |
| WHO grade III(3) d | 165 | 0.04 (0.04–0.05) | 84 | 0.05 (0.04–0.05) | 81 | 0.04 (0.04–0.05) | — | — | 13 | 0.01 (0.01–0.02) | 150 | 0.09 (0.08–0.10) |
| CNS lymphoma | 1696 | 0.45 (0.44–0.46) | 866 | 0.49 (0.48–0.51) | 831 | 0.41 (0.39–0.42) | 18 | 0.03 (0.02–0.04) | 106 | 0.10 (0.09–0.11) | 1572 | 0.94 (0.92–0.96) |
| Embryonal tumors | 634 | 0.22 (0.21–0.22) | 382 | 0.26 (0.25–0.27) | 252 | 0.18 (0.17–0.19) | 429 | 0.71 (0.68–0.74) | 151 | 0.14 (0.13–0.15) | 54 | 0.04 (0.03–0.04) |
| Medulloblastomak | 450 | 0.15 (0.15–0.16) | 287 | 0.19 (0.18–0.20) | 163 | 0.11 (0.11–0.12) | 293 | 0.48 (0.46–0.51) | 127 | 0.11 (0.11–0.12) | 31 | 0.02 (0.02–0.03) |
| SHH-activated and TP53-wildtype f | 80 | 0.03 (0.02–0.03) | 52 | 0.03 (0.03–0.04) | 29 | 0.02 (0.01–0.03) | 36 | 0.06 (0.05–0.08) | 38 | 0.03 (0.03–0.04) | — | — |
| SHH-activated and TP53-mutant f | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 14 | 0.01 (0.00–0.01) | — | — | 10 | 0.01 (0.00–0.01) | 12 | 0.02 (0.01–0.03) | — | — | — | — |
| Non-WNT/non-SHHf | 67 | 0.02 (0.02–0.03) | 44 | 0.03 (0.02–0.04) | 22 | 0.02 (0.01–0.02) | 55 | 0.09 (0.08–0.11) | 10 | 0.01 (0.01–0.01) | — | — |
| AT/RTl | 82 | 0.03 (0.03–0.03) | 42 | 0.03 (0.02–0.03) | 41 | 0.03 (0.02–0.03) | 73 | 0.12 (0.11–0.13) | 6 | 0.01 (0.00–0.01) | 3 | 0.00 (0.00–0.00) |
| Germ cell tumors | 256 | 0.09 (0.08–0.09) | 188 | 0.12 (0.12–0.13) | 68 | 0.05 (0.04–0.05) | 116 | 0.19 (0.18–0.21) | 125 | 0.11 (0.10–0.12) | 15 | 0.01 (0.01–0.01) |
| Cranial and paraspinal nerve tumors | 7403 | 2.05 (2.03–2.07) | 3553 | 2.05 (2.02–2.08) | 3850 | 2.06 (2.03–2.09) | 137 | 0.23 (0.21–0.24) | 1102 | 1.04 (1.02–1.07) | 6164 | 3.79 (3.74–3.83) |
| Tumors of the pituitary | 15 373 | 4.50 (4.47–4.53) | 6796 | 3.98 (3.94–4.03) | 8576 | 5.10 (5.05–5.15) | 223 | 0.37 (0.35–0.39) | 4596 | 4.26 (4.21–4.32) | 10 554 | 6.75 (6.69–6.81) |
| Histopathology (tumor type) . | Race . | Hispanic Ethnicity . | ||||||||||
| White . | Black . | AIAN . | API . | Non-Hispanic . | Hispanic . | |||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 18 735 | 6.45 (6.40–6.49) | 1569 | 3.53 (3.45–3.61) | 125 | 2.92 (2.69–3.17) | 481 | 2.33 (2.24–2.43) | 19 130 | 6.20 (6.16–6.24) | 2232 | 4.63 (4.54–4.72) |
| Glioblastoma | 11 354 | 3.55 (3.52–3.58) | 796 | 1.82 (1.76–1.88) | 59 | 1.50 (1.33–1.70) | 248 | 1.20 (1.13–1.27) | 11 566 | 3.36 (3.33–3.39) | 1086 | 2.59 (2.52–2.66) |
| Diffuse and anaplastic astrocytoma | 2565 | 0.95 (0.94–0.97) | 211 | 0.47 (0.45–0.50) | 17 | 0.37 (0.29–0.46) | 77 | 0.36 (0.33–0.40) | 2623 | 0.92 (0.91–0.94) | 313 | 0.60 (0.57–0.63) |
| WHO grade II(2) d | 775 | 0.31 (0.30–0.32) | 67 | 0.15 (0.13–0.17) | 5 | 0.11 (0.07–0.16) | 25 | 0.12 (0.10–0.14) | 794 | 0.30 (0.29–0.31) | 102 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 1224 | 0.45 (0.43–0.46) | 91 | 0.21 (0.19–0.23) | 7 | 0.17 (0.12–0.24) | 33 | 0.15 (0.13–0.18) | 1245 | 0.43 (0.41–0.44) | 137 | 0.26 (0.24–0.28) |
| Oligodendroglial tumorse | 975 | 0.39 (0.37–0.40) | 62 | 0.14 (0.13–0.16) | 12 | 0.27 (0.20–0.35) | 31 | 0.14 (0.12–0.17) | 965 | 0.36 (0.35–0.37) | 146 | 0.27 (0.25–0.30) |
| WHO grade II(2) d | 538 | 0.22 (0.21–0.23) | 32 | 0.07 (0.06–0.09) | 7 | 0.16 (0.12–0.23) | 15 | 0.07 (0.05–0.08) | 529 | 0.20 (0.20–0.21) | 79 | 0.15 (0.13–0.16) |
| WHO grade III(3) d | 326 | 0.12 (0.12–0.13) | 19 | 0.04 (0.04–0.05) | — | — | 12 | 0.06 (0.04–0.07) | 321 | 0.11 (0.11–0.12) | 48 | 0.09 (0.08–0.11) |
| Pilocytic astrocytoma | 854 | 0.38 (0.37–0.40) | 132 | 0.28 (0.26–0.30) | 10 | 0.19 (0.14–0.25) | 26 | 0.14 (0.11–0.16) | 899 | 0.40 (0.39–0.41) | 169 | 0.25 (0.23–0.26) |
| Molecularly defined adult-type diffuse glioma f | 11 278 | 3.67 (3.62–3.72) | 804 | 1.79 (1.70–1.88) | 74 | 1.72 (1.45–2.03) | 266 | 1.20 (1.10–1.31) | 11 513 | 3.50 (3.45–3.55) | 1160 | 2.44 (2.34–2.55) |
| Astrocytoma, IDH-mutant | 1250 | 0.51 (0.49–0.53) | 96 | 0.21 (0.18–0.25) | — | — | 30 | 0.13 (0.10–0.17) | 1268 | 0.49 (0.47–0.51) | 153 | 0.27 (0.24–0.30) |
| WHO grade II(2) d | 368 | 0.15 (0.14–0.17) | 27 | 0.06 (0.05–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 378 | 0.15 (0.14–0.16) | 44 | 0.08 (0.06–0.10) |
| WHO grade III(3) d | 425 | 0.18 (0.16–0.19) | 28 | 0.06 (0.05–0.08) | — | — | — | — | 421 | 0.17 (0.15–0.18) | 52 | 0.09 (0.07–0.11) |
| WHO grade IV(4)d | 242 | 0.09 (0.09–0.10) | 23 | 0.05 (0.04–0.07) | — | — | — | — | 256 | 0.09 (0.09–0.10) | 26 | 0.05 (0.04–0.06) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 9205 | 2.84 (2.79–2.88) | 662 | 1.46 (1.38–1.55) | 55 | 1.32 (1.08–1.60) | 208 | 0.94 (0.85–1.04) | 9434 | 2.71 (2.67–2.75) | 879 | 1.94 (1.84–2.03) |
| WHO grade II(2)d | 167 | 0.06 (0.05–0.07) | 18 | 0.04 (0.03–0.05) | — | — | — | — | 178 | 0.06 (0.05–0.07) | 19 | 0.04 (0.03–0.05) |
| WHO grade III(3)d | 330 | 0.11 (0.10–0.12) | 29 | 0.07 (0.05–0.09) | — | — | 10 | 0.05 (0.03–0.07) | 350 | 0.11 (0.10–0.12) | 30 | 0.06 (0.04–0.08) |
| WHO grade IV(4)d | 6609 | 2.02 (1.98–2.05) | 472 | 1.04 (0.97–1.11) | 37 | 0.90 (0.70–1.14) | 144 | 0.65 (0.58–0.74) | 6760 | 1.92 (1.89–1.95) | 626 | 1.39 (1.31–1.47) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleleted | 823 | 0.33 (0.31–0.34) | 47 | 0.11 (0.09–0.13) | 12 | 0.26 (0.17–0.39) | 29 | 0.13 (0.10–0.16) | 812 | 0.31 (0.29–0.32) | 128 | 0.24 (0.21–0.27) |
| WHO grade II(2)d | 406 | 0.17 (0.16–0.18) | 25 | 0.06 (0.04–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 402 | 0.16 (0.15–0.17) | 68 | 0.12 (0.10–0.15) |
| WHO grade III(3)d | 284 | 0.11 (0.10–0.12) | 16 | 0.04 (0.02–0.05) | — | — | 11 | 0.05 (0.03–0.07) | 278 | 0.10 (0.09–0.11) | 42 | 0.08 (0.06–0.10) |
| Ependymal tumors | 1170 | 0.45 (0.44–0.46) | 123 | 0.27 (0.25–0.30) | 11 | 0.24 (0.18–0.31) | 36 | 0.17 (0.15–0.20) | 1179 | 0.43 (0.42–0.44) | 204 | 0.36 (0.34–0.39) |
| Spinal ependymoma g | 564 | 0.22 (0.21–0.23) | 47 | 0.11 (0.09–0.12) | 5 | 0.11 (0.07–0.17) | 17 | 0.08 (0.06–0.09) | 562 | 0.21 (0.20–0.21) | 92 | 0.17 (0.15–0.18) |
| Supratentorial ependymoma | 87 | 0.04 (0.03–0.04) | 15 | 0.03 (0.03–0.04) | — | — | 5 | 0.03 (0.02–0.04) | 93 | 0.04 (0.03–0.04) | 18 | 0.03 (0.02–0.04) |
| Infratentorial ependymomai | 397 | 0.15 (0.14–0.16) | 46 | 0.10 (0.09–0.12) | — | — | 10 | 0.05 (0.04–0.07) | 401 | 0.14 (0.14–0.15) | 68 | 0.12 (0.11–0.14) |
| Diffuse midline glioma, H3 K27M-mutantf | 122 | 0.05 (0.05–0.06) | 24 | 0.05 (0.04–0.07) | — | 8 | 0.04 (0.03–0.07) | 126 | 0.06 (0.05–0.06) | 39 | 0.06 (0.05–0.07) | |
| High-grade glioma of the brainstem j | 427 | 0.18 (0.17–0.19) | 81 | 0.17 (0.16–0.19) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 454 | 0.18 (0.18–0.19) | 92 | 0.15 (0.13–0.16) |
| Meningiomas | 28 753 | 9.27 (9.22–9.32) | 4592 | 11.12 (10.97–11.27) | 219 | 5.98 (5.61–6.37) | 1359 | 6.81 (6.65–6.98) | 32 046 | 9.62 (9.57–9.66) | 3643 | 9.02 (8.88–9.15) |
| WHO grade I(1)d | 9572 | 3.16 (3.13–3.19) | 1538 | 3.62 (3.54–3.71) | 83 | 2.14 (1.93–2.37) | 466 | 2.23 (2.14–2.32) | 10 714 | 3.29 (3.26–3.32) | 1220 | 2.79 (2.71–2.86) |
| WHO grade II(2) d | 1496 | 0.50 (0.49–0.52) | 316 | 0.73 (0.69–0.77) | 12 | 0.31 (0.23–0.40) | 103 | 0.50 (0.45–0.54) | 1777 | 0.56 (0.55–0.57) | 199 | 0.44 (0.42–0.47) |
| WHO grade III(3) d | 129 | 0.04 (0.04–0.05) | 24 | 0.05 (0.04–0.07) | — | — | 10 | 0.05 (0.04–0.06) | 145 | 0.04 (0.04–0.05) | 20 | 0.05 (0.04–0.06) |
| CNS lymphoma | 1417 | 0.45 (0.43–0.46) | 135 | 0.31 (0.29–0.34) | 11 | 0.30 (0.23–0.40) | 95 | 0.47 (0.43–0.51) | 1485 | 0.44 (0.43–0.45) | 211 | 0.51 (0.48–0.54) |
| Embryonal tumors | 503 | 0.23 (0.22–0.24) | 74 | 0.15 (0.14–0.17) | 7 | 0.14 (0.10–0.20) | 24 | 0.13 (0.11–0.16) | 491 | 0.22 (0.21–0.23) | 143 | 0.21 (0.19–0.23) |
| Medulloblastoma k | 359 | 0.16 (0.16–0.17) | 49 | 0.10 (0.09–0.12) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 347 | 0.16 (0.15–0.16) | 104 | 0.15 (0.14–0.17) |
| SHH-activated and TP53-wildtypef | 60 | 0.03 (0.02–0.03) | 10 | 0.02 (0.01–0.03) | — | — | — | — | 62 | 0.03 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| SHH-activated and TP53-mutantf | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 11 | 0.01 (0.00–0.01) | — | — | — | — | — | — | 12 | 0.01 (0.00–0.01) | — | — |
| Non-WNT/non-SHHf | 58 | 0.03 (0.02–0.03) | — | — | — | — | — | — | 48 | 0.02 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| AT/RTl | 63 | 0.03 (0.03–0.03) | 12 | 0.02 (0.02–0.03) | — | — | 4 | 0.02 (0.02–0.04) | 64 | 0.03 (0.03–0.03) | 18 | 0.03 (0.02–0.03) |
| Germ cell tumors | 192 | 0.09 (0.08–0.09) | 30 | 0.06 (0.05–0.07) | — | — | 22 | 0.11 (0.09–0.14) | 199 | 0.09 (0.08–0.09) | 57 | 0.08 (0.07–0.09) |
| Cranial and paraspinal nerve tumors | 6253 | 2.15 (2.12–2.17) | 463 | 1.05 (1.01–1.09) | 48 | 1.14 (1.00–1.30) | 383 | 1.78 (1.70–1.87) | 6699 | 2.15 (2.13–2.18) | 704 | 1.45 (1.40–1.50) |
| Tumors of the pituitary | 10 941 | 4.05 (4.01–4.09) | 3079 | 7.10 (6.98–7.21) | 143 | 3.37 (3.11–3.63) | 648 | 3.04 (2.93–3.15) | 12 755 | 4.39 (4.35–4.43) | 2618 | 5.15 (5.06–5.24) |
| Histopathology (tumor type) . | Total . | Sex . | Age at diagnosis . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Male . | Female . | 0–14 years . | 15–39 years . | 40+ Years . | ||||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR 95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 21 362 | 5.94 (5.91–5.98) | 12 104 | 7.05 (6.99–7.10) | 9258 | 4.97 (4.92–5.02) | 1795 | 2.96 (2.90–3.02) | 3170 | 2.95 (2.91–3.00) | 16 397 | 9.90 (9.83–9.97) |
| Glioblastoma | 12 652 | 3.26 (3.24–3.29) | 7365 | 4.08 (4.04–4.12) | 5286 | 2.55 (2.52–2.59) | 93 | 0.15 (0.14–0.17) | 608 | 0.58 (0.56–0.60) | 11 951 | 7.03 (6.97–7.09) |
| Diffuse and anaplastic astrocytoma | 2936 | 0.87 (0.85–0.88) | 1623 | 0.98 (0.96–1.01) | 1313 | 0.75 (0.74–0.77) | 170 | 0.28 (0.26–0.30) | 932 | 0.86 (0.83–0.88) | 1834 | 1.16 (1.14–1.19) |
| WHO grade II(2)d | 896 | 0.28 (0.27–0.28) | 510 | 0.32 (0.31–0.33) | 386 | 0.23 (0.22–0.25) | 49 | 0.08 (0.07–0.09) | 388 | 0.36 (0.34–0.37) | 459 | 0.30 (0.29–0.32) |
| WHO grade III(3)d | 1382 | 0.40 (0.39–0.41) | 764 | 0.46 (0.44–0.47) | 618 | 0.35 (0.33–0.36) | 38 | 0.06 (0.05–0.07) | 406 | 0.37 (0.36–0.39) | 939 | 0.59 (0.57–0.61) |
Oligodendroglial tumorse | 1112 | 0.34 (0.33–0.35) | 615 | 0.39 (0.37–0.40) | 497 | 0.30 (0.29–0.31) | 15 | 0.02 (0.02–0.03) | 389 | 0.37 (0.35–0.38) | 708 | 0.48 (0.47–0.50) |
| WHO grade II(2)d | 608 | 0.19 (0.19–0.20) | 333 | 0.21 (0.20–0.22) | 276 | 0.17 (0.16–0.18) | 7 | 0.01 (0.01–0.02) | 244 | 0.23 (0.22–0.24) | 357 | 0.25 (0.24–0.27) |
| WHO grade III(3)d | 369 | 0.11 (0.11–0.12) | 204 | 0.13 (0.12–0.13) | 164 | 0.10 (0.09–0.10) | — | — | 104 | 0.10 (0.09–0.11) | 263 | 0.18 (0.17–0.19) |
| Pilocytic astrocytoma | 1068 | 0.36 (0.35–0.37) | 561 | 0.38 (0.36–0.39) | 507 | 0.35 (0.34–0.36) | 657 | 1.08 (1.04–1.12) | 293 | 0.27 (0.26–0.28) | 119 | 0.08 (0.07–0.09) |
| Molecularly-defined adult-type diffuse gliomaf | 12 674 | 3.34 (3.30–3.38) | 7400 | 4.11 (4.04–4.18) | 5273 | 2.66 (2.60–2.71) | 136 | 0.23 (0.20–0.26) | 1643 | 1.53 (1.47–1.58) | 10 894 | 6.39 (6.31–6.48) |
| Astrocytoma, IDH-mutant | 1421 | 0.44 (0.43–0.46) | 814 | 0.51 (0.49–0.54) | 608 | 0.38 (0.35–0.40) | 33 | 0.05 (0.04–0.07) | 740 | 0.68 (0.64–0.71) | 648 | 0.45 (0.42–0.47) |
| WHO grade II(2) d | 422 | 0.14 (0.13–0.15) | 248 | 0.16 (0.15–0.17) | 175 | 0.11 (0.10–0.13) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 149 | 0.11 (0.10–0.12) |
| WHO grade III(3) d | 474 | 0.15 (0.14–0.16) | 270 | 0.17 (0.16–0.19) | 203 | 0.13 (0.12–0.14) | 8 | 0.01 (0.01–0.02) | 265 | 0.24 (0.22–0.26) | 200 | 0.14 (0.13–0.16) |
| WHO grade IV(4) d | 282 | 0.09 (0.08–0.09) | 163 | 0.10 (0.09–0.11) | 120 | 0.07 (0.06–0.08) | — | — | 118 | 0.11 (0.10–0.13) | 162 | 0.11 (0.09–0.12) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 10 312 | 2.61 (2.57–2.64) | 6070 | 3.27 (3.21–3.33) | 4243 | 2.02 (1.98–2.07) | 96 | 0.16 (0.14–0.18) | 562 | 0.53 (0.50–0.56) | 9654 | 5.54 (5.46–5.62) |
| WHO grade II(2) d | 197 | 0.06 (0.05–0.06) | 106 | 0.06 (0.05–0.07) | 92 | 0.05 (0.04–0.06) | 17 | 0.03 (0.02–0.04) | 46 | 0.04 (0.03–0.05) | 134 | 0.08 (0.07–0.09) |
| WHO grade III(3) d | 381 | 0.10 (0.10–0.11) | 206 | 0.12 (0.11–0.13) | 176 | 0.09 (0.08–0.10) | 10 | 0.02 (0.01–0.02) | 64 | 0.06 (0.05–0.07) | 307 | 0.18 (0.17–0.20) |
| WHO grade IV(4) d | 7386 | 1.85 (1.82–1.88) | 4416 | 2.36 (2.31–2.41) | 2970 | 1.40 (1.37–1.44) | 44 | 0.07 (0.06–0.09) | 334 | 0.32 (0.29–0.34) | 7009 | 4.01 (3.94–4.08) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleted | 940 | 0.29 (0.28–0.31) | 518 | 0.33 (0.31–0.35) | 422 | 0.26 (0.24–0.28) | — | — | 342 | 0.32 (0.30–0.35) | 591 | 0.41 (0.38–0.43) |
| WHO grade II(2) d | 470 | 0.15 (0.14–0.16) | 257 | 0.17 (0.15–0.18) | 213 | 0.13 (0.12–0.15) | — | — | 199 | 0.19 (0.17–0.20) | 265 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 320 | 0.10 (0.09–0.10) | 180 | 0.11 (0.10–0.12) | 140 | 0.08 (0.07–0.09) | — | — | 100 | 0.09 (0.08–0.11) | 220 | 0.15 (0.13–0.16) |
| Ependymal tumors | 1382 | 0.42 (0.41–0.43) | 793 | 0.49 (0.47–0.50) | 589 | 0.35 (0.34–0.37) | 185 | 0.30 (0.28–0.32) | 385 | 0.36 (0.34–0.38) | 812 | 0.53 (0.51–0.54) |
| Spinal ependymomag | 654 | 0.20 (0.19–0.21) | 352 | 0.22 (0.21–0.23) | 302 | 0.18 (0.17–0.19) | 28 | 0.05 (0.04–0.05) | 226 | 0.21 (0.20–0.22) | 400 | 0.26 (0.25–0.28) |
| Supratentorial ependymomah | 112 | 0.04 (0.03–0.04) | 57 | 0.04 (0.03–0.04) | 55 | 0.03 (0.03–0.04) | 36 | 0.06 (0.05–0.07) | 30 | 0.03 (0.02–0.03) | 45 | 0.03 (0.03–0.03) |
| Infratentorial (posterior fossa) ependymomai | 468 | 0.14 (0.13–0.15) | 295 | 0.18 (0.17–0.19) | 173 | 0.10 (0.10–0.11) | 78 | 0.13 (0.12–0.14) | 96 | 0.09 (0.08–0.10) | 294 | 0.19 (0.18–0.20) |
| Diffuse midline glioma, H3 K27M-mutantf | 166 | 0.06 (0.05–0.06) | 75 | 0.05 (0.04–0.06) | 90 | 0.06 (0.05–0.07) | 84 | 0.14 (0.12–0.16) | 53 | 0.05 (0.04–0.06) | 29 | 0.02 (0.02–0.03) |
| High-grade glioma of the brainstemj | 547 | 0.18 (0.17–0.18) | 278 | 0.18 (0.17–0.19) | 269 | 0.18 (0.17–0.19) | 232 | 0.38 (0.36–0.41) | 141 | 0.13 (0.12–0.14) | 173 | 0.11 (0.10–0.12) |
| Meningiomas | 35 689 | 9.51 (9.46–9.55) | 9667 | 5.64 (5.59–5.69) | 26 022 | 12.95 (12.87–13.02) | 64 | 0.10 (0.09–0.12) | 2025 | 1.97 (1.93–2.01) | 33 600 | 20.41 (20.31–20.51) |
| WHO grade I(1) d | 11 934 | 3.22 (3.20–3.25) | 3224 | 1.85 (1.82–1.88) | 8710 | 4.49 (4.44–4.53) | 22 | 0.04 (0.03–0.04) | 915 | 0.90 (0.87–0.92) | 10 997 | 6.73 (6.67–6.79) |
| WHO grade II(2) d | 1975 | 0.54 (0.53–0.55) | 827 | 0.47 (0.46–0.49) | 1148 | 0.61 (0.59–0.62) | 16 | 0.03 (0.02–0.03) | 216 | 0.21 (0.19–0.22) | 1743 | 1.07 (1.05–1.09) |
| WHO grade III(3) d | 165 | 0.04 (0.04–0.05) | 84 | 0.05 (0.04–0.05) | 81 | 0.04 (0.04–0.05) | — | — | 13 | 0.01 (0.01–0.02) | 150 | 0.09 (0.08–0.10) |
| CNS lymphoma | 1696 | 0.45 (0.44–0.46) | 866 | 0.49 (0.48–0.51) | 831 | 0.41 (0.39–0.42) | 18 | 0.03 (0.02–0.04) | 106 | 0.10 (0.09–0.11) | 1572 | 0.94 (0.92–0.96) |
| Embryonal tumors | 634 | 0.22 (0.21–0.22) | 382 | 0.26 (0.25–0.27) | 252 | 0.18 (0.17–0.19) | 429 | 0.71 (0.68–0.74) | 151 | 0.14 (0.13–0.15) | 54 | 0.04 (0.03–0.04) |
| Medulloblastomak | 450 | 0.15 (0.15–0.16) | 287 | 0.19 (0.18–0.20) | 163 | 0.11 (0.11–0.12) | 293 | 0.48 (0.46–0.51) | 127 | 0.11 (0.11–0.12) | 31 | 0.02 (0.02–0.03) |
| SHH-activated and TP53-wildtype f | 80 | 0.03 (0.02–0.03) | 52 | 0.03 (0.03–0.04) | 29 | 0.02 (0.01–0.03) | 36 | 0.06 (0.05–0.08) | 38 | 0.03 (0.03–0.04) | — | — |
| SHH-activated and TP53-mutant f | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 14 | 0.01 (0.00–0.01) | — | — | 10 | 0.01 (0.00–0.01) | 12 | 0.02 (0.01–0.03) | — | — | — | — |
| Non-WNT/non-SHHf | 67 | 0.02 (0.02–0.03) | 44 | 0.03 (0.02–0.04) | 22 | 0.02 (0.01–0.02) | 55 | 0.09 (0.08–0.11) | 10 | 0.01 (0.01–0.01) | — | — |
| AT/RTl | 82 | 0.03 (0.03–0.03) | 42 | 0.03 (0.02–0.03) | 41 | 0.03 (0.02–0.03) | 73 | 0.12 (0.11–0.13) | 6 | 0.01 (0.00–0.01) | 3 | 0.00 (0.00–0.00) |
| Germ cell tumors | 256 | 0.09 (0.08–0.09) | 188 | 0.12 (0.12–0.13) | 68 | 0.05 (0.04–0.05) | 116 | 0.19 (0.18–0.21) | 125 | 0.11 (0.10–0.12) | 15 | 0.01 (0.01–0.01) |
| Cranial and paraspinal nerve tumors | 7403 | 2.05 (2.03–2.07) | 3553 | 2.05 (2.02–2.08) | 3850 | 2.06 (2.03–2.09) | 137 | 0.23 (0.21–0.24) | 1102 | 1.04 (1.02–1.07) | 6164 | 3.79 (3.74–3.83) |
| Tumors of the pituitary | 15 373 | 4.50 (4.47–4.53) | 6796 | 3.98 (3.94–4.03) | 8576 | 5.10 (5.05–5.15) | 223 | 0.37 (0.35–0.39) | 4596 | 4.26 (4.21–4.32) | 10 554 | 6.75 (6.69–6.81) |
| Histopathology (tumor type) . | Race . | Hispanic Ethnicity . | ||||||||||
| White . | Black . | AIAN . | API . | Non-Hispanic . | Hispanic . | |||||||
| Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | Annual average . | AAAIR (95% CI) . | |
| All gliomasc | 18 735 | 6.45 (6.40–6.49) | 1569 | 3.53 (3.45–3.61) | 125 | 2.92 (2.69–3.17) | 481 | 2.33 (2.24–2.43) | 19 130 | 6.20 (6.16–6.24) | 2232 | 4.63 (4.54–4.72) |
| Glioblastoma | 11 354 | 3.55 (3.52–3.58) | 796 | 1.82 (1.76–1.88) | 59 | 1.50 (1.33–1.70) | 248 | 1.20 (1.13–1.27) | 11 566 | 3.36 (3.33–3.39) | 1086 | 2.59 (2.52–2.66) |
| Diffuse and anaplastic astrocytoma | 2565 | 0.95 (0.94–0.97) | 211 | 0.47 (0.45–0.50) | 17 | 0.37 (0.29–0.46) | 77 | 0.36 (0.33–0.40) | 2623 | 0.92 (0.91–0.94) | 313 | 0.60 (0.57–0.63) |
| WHO grade II(2) d | 775 | 0.31 (0.30–0.32) | 67 | 0.15 (0.13–0.17) | 5 | 0.11 (0.07–0.16) | 25 | 0.12 (0.10–0.14) | 794 | 0.30 (0.29–0.31) | 102 | 0.19 (0.17–0.21) |
| WHO grade III(3) d | 1224 | 0.45 (0.43–0.46) | 91 | 0.21 (0.19–0.23) | 7 | 0.17 (0.12–0.24) | 33 | 0.15 (0.13–0.18) | 1245 | 0.43 (0.41–0.44) | 137 | 0.26 (0.24–0.28) |
| Oligodendroglial tumorse | 975 | 0.39 (0.37–0.40) | 62 | 0.14 (0.13–0.16) | 12 | 0.27 (0.20–0.35) | 31 | 0.14 (0.12–0.17) | 965 | 0.36 (0.35–0.37) | 146 | 0.27 (0.25–0.30) |
| WHO grade II(2) d | 538 | 0.22 (0.21–0.23) | 32 | 0.07 (0.06–0.09) | 7 | 0.16 (0.12–0.23) | 15 | 0.07 (0.05–0.08) | 529 | 0.20 (0.20–0.21) | 79 | 0.15 (0.13–0.16) |
| WHO grade III(3) d | 326 | 0.12 (0.12–0.13) | 19 | 0.04 (0.04–0.05) | — | — | 12 | 0.06 (0.04–0.07) | 321 | 0.11 (0.11–0.12) | 48 | 0.09 (0.08–0.11) |
| Pilocytic astrocytoma | 854 | 0.38 (0.37–0.40) | 132 | 0.28 (0.26–0.30) | 10 | 0.19 (0.14–0.25) | 26 | 0.14 (0.11–0.16) | 899 | 0.40 (0.39–0.41) | 169 | 0.25 (0.23–0.26) |
| Molecularly defined adult-type diffuse glioma f | 11 278 | 3.67 (3.62–3.72) | 804 | 1.79 (1.70–1.88) | 74 | 1.72 (1.45–2.03) | 266 | 1.20 (1.10–1.31) | 11 513 | 3.50 (3.45–3.55) | 1160 | 2.44 (2.34–2.55) |
| Astrocytoma, IDH-mutant | 1250 | 0.51 (0.49–0.53) | 96 | 0.21 (0.18–0.25) | — | — | 30 | 0.13 (0.10–0.17) | 1268 | 0.49 (0.47–0.51) | 153 | 0.27 (0.24–0.30) |
| WHO grade II(2) d | 368 | 0.15 (0.14–0.17) | 27 | 0.06 (0.05–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 378 | 0.15 (0.14–0.16) | 44 | 0.08 (0.06–0.10) |
| WHO grade III(3) d | 425 | 0.18 (0.16–0.19) | 28 | 0.06 (0.05–0.08) | — | — | — | — | 421 | 0.17 (0.15–0.18) | 52 | 0.09 (0.07–0.11) |
| WHO grade IV(4)d | 242 | 0.09 (0.09–0.10) | 23 | 0.05 (0.04–0.07) | — | — | — | — | 256 | 0.09 (0.09–0.10) | 26 | 0.05 (0.04–0.06) |
| Astrocytoma, IDH-wildtype (glioblastoma, IDH-wildtype) | 9205 | 2.84 (2.79–2.88) | 662 | 1.46 (1.38–1.55) | 55 | 1.32 (1.08–1.60) | 208 | 0.94 (0.85–1.04) | 9434 | 2.71 (2.67–2.75) | 879 | 1.94 (1.84–2.03) |
| WHO grade II(2)d | 167 | 0.06 (0.05–0.07) | 18 | 0.04 (0.03–0.05) | — | — | — | — | 178 | 0.06 (0.05–0.07) | 19 | 0.04 (0.03–0.05) |
| WHO grade III(3)d | 330 | 0.11 (0.10–0.12) | 29 | 0.07 (0.05–0.09) | — | — | 10 | 0.05 (0.03–0.07) | 350 | 0.11 (0.10–0.12) | 30 | 0.06 (0.04–0.08) |
| WHO grade IV(4)d | 6609 | 2.02 (1.98–2.05) | 472 | 1.04 (0.97–1.11) | 37 | 0.90 (0.70–1.14) | 144 | 0.65 (0.58–0.74) | 6760 | 1.92 (1.89–1.95) | 626 | 1.39 (1.31–1.47) |
| Oligodendroglioma, IDH-mutant and 1p/19q-codeleleted | 823 | 0.33 (0.31–0.34) | 47 | 0.11 (0.09–0.13) | 12 | 0.26 (0.17–0.39) | 29 | 0.13 (0.10–0.16) | 812 | 0.31 (0.29–0.32) | 128 | 0.24 (0.21–0.27) |
| WHO grade II(2)d | 406 | 0.17 (0.16–0.18) | 25 | 0.06 (0.04–0.08) | — | — | 14 | 0.06 (0.04–0.09) | 402 | 0.16 (0.15–0.17) | 68 | 0.12 (0.10–0.15) |
| WHO grade III(3)d | 284 | 0.11 (0.10–0.12) | 16 | 0.04 (0.02–0.05) | — | — | 11 | 0.05 (0.03–0.07) | 278 | 0.10 (0.09–0.11) | 42 | 0.08 (0.06–0.10) |
| Ependymal tumors | 1170 | 0.45 (0.44–0.46) | 123 | 0.27 (0.25–0.30) | 11 | 0.24 (0.18–0.31) | 36 | 0.17 (0.15–0.20) | 1179 | 0.43 (0.42–0.44) | 204 | 0.36 (0.34–0.39) |
| Spinal ependymoma g | 564 | 0.22 (0.21–0.23) | 47 | 0.11 (0.09–0.12) | 5 | 0.11 (0.07–0.17) | 17 | 0.08 (0.06–0.09) | 562 | 0.21 (0.20–0.21) | 92 | 0.17 (0.15–0.18) |
| Supratentorial ependymoma | 87 | 0.04 (0.03–0.04) | 15 | 0.03 (0.03–0.04) | — | — | 5 | 0.03 (0.02–0.04) | 93 | 0.04 (0.03–0.04) | 18 | 0.03 (0.02–0.04) |
| Infratentorial ependymomai | 397 | 0.15 (0.14–0.16) | 46 | 0.10 (0.09–0.12) | — | — | 10 | 0.05 (0.04–0.07) | 401 | 0.14 (0.14–0.15) | 68 | 0.12 (0.11–0.14) |
| Diffuse midline glioma, H3 K27M-mutantf | 122 | 0.05 (0.05–0.06) | 24 | 0.05 (0.04–0.07) | — | 8 | 0.04 (0.03–0.07) | 126 | 0.06 (0.05–0.06) | 39 | 0.06 (0.05–0.07) | |
| High-grade glioma of the brainstem j | 427 | 0.18 (0.17–0.19) | 81 | 0.17 (0.16–0.19) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 454 | 0.18 (0.18–0.19) | 92 | 0.15 (0.13–0.16) |
| Meningiomas | 28 753 | 9.27 (9.22–9.32) | 4592 | 11.12 (10.97–11.27) | 219 | 5.98 (5.61–6.37) | 1359 | 6.81 (6.65–6.98) | 32 046 | 9.62 (9.57–9.66) | 3643 | 9.02 (8.88–9.15) |
| WHO grade I(1)d | 9572 | 3.16 (3.13–3.19) | 1538 | 3.62 (3.54–3.71) | 83 | 2.14 (1.93–2.37) | 466 | 2.23 (2.14–2.32) | 10 714 | 3.29 (3.26–3.32) | 1220 | 2.79 (2.71–2.86) |
| WHO grade II(2) d | 1496 | 0.50 (0.49–0.52) | 316 | 0.73 (0.69–0.77) | 12 | 0.31 (0.23–0.40) | 103 | 0.50 (0.45–0.54) | 1777 | 0.56 (0.55–0.57) | 199 | 0.44 (0.42–0.47) |
| WHO grade III(3) d | 129 | 0.04 (0.04–0.05) | 24 | 0.05 (0.04–0.07) | — | — | 10 | 0.05 (0.04–0.06) | 145 | 0.04 (0.04–0.05) | 20 | 0.05 (0.04–0.06) |
| CNS lymphoma | 1417 | 0.45 (0.43–0.46) | 135 | 0.31 (0.29–0.34) | 11 | 0.30 (0.23–0.40) | 95 | 0.47 (0.43–0.51) | 1485 | 0.44 (0.43–0.45) | 211 | 0.51 (0.48–0.54) |
| Embryonal tumors | 503 | 0.23 (0.22–0.24) | 74 | 0.15 (0.14–0.17) | 7 | 0.14 (0.10–0.20) | 24 | 0.13 (0.11–0.16) | 491 | 0.22 (0.21–0.23) | 143 | 0.21 (0.19–0.23) |
| Medulloblastoma k | 359 | 0.16 (0.16–0.17) | 49 | 0.10 (0.09–0.12) | 6 | 0.12 (0.08–0.18) | 17 | 0.09 (0.07–0.11) | 347 | 0.16 (0.15–0.16) | 104 | 0.15 (0.14–0.17) |
| SHH-activated and TP53-wildtypef | 60 | 0.03 (0.02–0.03) | 10 | 0.02 (0.01–0.03) | — | — | — | — | 62 | 0.03 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| SHH-activated and TP53-mutantf | — | — | — | — | — | — | — | — | — | — | — | — |
| WNT-activatedf | 11 | 0.01 (0.00–0.01) | — | — | — | — | — | — | 12 | 0.01 (0.00–0.01) | — | — |
| Non-WNT/non-SHHf | 58 | 0.03 (0.02–0.03) | — | — | — | — | — | — | 48 | 0.02 (0.02–0.03) | 18 | 0.03 (0.02–0.04) |
| AT/RTl | 63 | 0.03 (0.03–0.03) | 12 | 0.02 (0.02–0.03) | — | — | 4 | 0.02 (0.02–0.04) | 64 | 0.03 (0.03–0.03) | 18 | 0.03 (0.02–0.03) |
| Germ cell tumors | 192 | 0.09 (0.08–0.09) | 30 | 0.06 (0.05–0.07) | — | — | 22 | 0.11 (0.09–0.14) | 199 | 0.09 (0.08–0.09) | 57 | 0.08 (0.07–0.09) |
| Cranial and paraspinal nerve tumors | 6253 | 2.15 (2.12–2.17) | 463 | 1.05 (1.01–1.09) | 48 | 1.14 (1.00–1.30) | 383 | 1.78 (1.70–1.87) | 6699 | 2.15 (2.13–2.18) | 704 | 1.45 (1.40–1.50) |
| Tumors of the pituitary | 10 941 | 4.05 (4.01–4.09) | 3079 | 7.10 (6.98–7.21) | 143 | 3.37 (3.11–3.63) | 648 | 3.04 (2.93–3.15) | 12 755 | 4.39 (4.35–4.43) | 2618 | 5.15 (5.06–5.24) |
aAnnual average cases are calculated by dividing the 5-year total by five.
bRates are per 100 000 and are age-adjusted to the 2000 US standard population.
cICD-O-3 histopathology codes 9380-9384, 9391-9460.
dMay not sum to total of all cases in histopathology (tumor type) due to missing grade information.
eIncludes “diffuse” oligodendroglioma and “anaplastic” oligodendroglioma.
fHistopathologies collected beginning in 2018 and onward, average annual totals and incidence rates are based on two years of cases only. Limited to cases with histopathologic confirmation only.
gIncludes ependymal tumors occurring in sites spine and cauda equina.
hIncludes ependymal tumors occurring in sites cerebellum, frontal lobe, occipital lobe, temporal love, and parietal lobe.
iIncludes ependymal tumors occurring in sites cerebrum, ventricle, and brain stem.
jDefined as high grade glioma (ICD-O-3 histopathology codes: 9380, 9381, 9400, 9401, 9440, 9441, 9442/3, 9451, and 9460) occurring in the brain stem (ICD-O-3 site code: C71.7). See Ostrom, et al.(1) Ostrom QT, Price M, Ryan K, Edelson J, Neff C, Cioffi G, Waite KA, Kruchko C, Barnholtz-Sloan JS (2022) CBTRUS Statistical Report: pediatric brain tumor foundation childhood and adolescent primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. Neuro Oncol. 24: iii1–iii38. doi: 10.1093/neuonc/noac161 for more information.
kICD-O-3 code 9470–9472, 9474–9477.
lICD-O-3 code 9508/3.
—Counts and rates are not presented when fewer than 16 cases were reported for the specific category for the 5-year period. The suppressed cases are included in the counts and rates for totals.
Abbreviations: AIAN, American Indian/Alaska Native; API, Asian or Pacific Islander; ATRT, Atypical teratoid/rhabdoid tumors; CBTRUS, Central Brain Tumor Registry of the United States; CI, confidence interval; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program; SHH: Sonic Hedgehog; WNT: Wingless.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
